Vascular endothelial growth factor (VEGF)-A and VEGF-A165b are associated with time to remission of granulomatosis with polyangiitis in a nationwide Japanese prospective cohort study

2020 ◽  
pp. 000456322096837
Author(s):  
Ryosuke Kikuchi ◽  
Naotake Tsuboi ◽  
Ken-Ei Sada ◽  
Masahiro Nakatochi ◽  
Yuki Yokoe ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Cohort Study ◽  
Growth Factor ◽  
Granulomatosis With Polyangiitis ◽  
Microscopic Polyangiitis ◽  
Antineutrophil Cytoplasmic Antibody ◽  
Eosinophilic Granulomatosis With Polyangiitis ◽  
Vascular Endothelial ◽  
Serum Samples ◽  
Endothelial Growth Factor

Background Effective prognostic markers are needed for antineutrophil cytoplasmic antibody-associated vasculitis (AAV). This study evaluated the clinical associations of serum vascular endothelial growth factor-A (sVEGF-A) and sVEGF-A165b (an antiangiogenic isoform of VEGF-A) concentrations with time to remission of AAV in a nationwide Japanese prospective follow-up cohort. Methods We collected samples from patients with AAV who were enrolled in the nationwide Japanese cohort study (RemIT-JAV-RPGN). We measured sVEGF-A and sVEGF-A165b concentrations using enzyme-linked immunosorbent assays in 57 serum samples collected 6 months before and after initiation of AAV treatment. Patients were classified based on AAV disease subtypes: microscopic polyangiitis, granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis (EGPA). Results Results revealed significant reductions in sVEGF-A and sVEGF-A165b concentrations in patients with microscopic polyangiitis and EGPA, respectively. However, despite the comparable concentrations of sVEGF-A and sVEGF-A165b during the 6 months of treatment in granulomatosis with polyangiitis patients, correlation analysis revealed that the differences in log2-transformed concentrations of sVEGF-A and sVEGF-A165b were inversely correlated with time to remission in granulomatosis with polyangiitis patients. Conclusion These results suggest that sVEGF-A and -A165b can serve as potential markers of time to remission in patients with granulomatosis with polyangiitis.

scholarly journals Affinity-Enhanced Multimeric VEGF (Vascular Endothelial Growth Factor) and PlGF (Placental Growth Factor) Variants for Specific Adsorption of sFlt-1 to Restore Angiogenic Balance in Preeclampsia

Hypertension ◽  
2020 ◽  
Vol 76 (4) ◽  
pp. 1176-1184 ◽  
Author(s):  
Mahsa Matin ◽  
Matthias Mörgelin ◽  
Jörg Stetefeld ◽  
Bernhard Schermer ◽  
Paul T. Brinkkoetter ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Ex Vivo ◽  
Placental Growth Factor ◽  
Vascular Endothelial ◽  
Single Chain ◽  
Serum Samples ◽  
Multisystem Disease ◽  
Angiogenic Balance ◽  
Endothelial Growth Factor

Preeclampsia is a potentially life-threatening multisystem disease affecting 4% to 8% of pregnant women after the 20th week of gestation. An excess of placental expressed antiangiogenic soluble VEGF (vascular endothelial growth factor)-receptor 1 (soluble FMS-like tyrosine kinase 1) scavenges VEGF and PlGF (placental growth factor), causing generalized endothelial dysfunction. Interventions to restore the angiogenic balance in preeclamptic pregnancies are intensively studied and improve maternal and neonatal outcomes. Especially extracorporeal strategies to remove sFlt-1 are promising in human pregnancy. However, available apheresis systems adsorb sFlt-1 unspecifically and with low efficiency. Affinity-enhanced ligands are needed to improve performance and compatibility of apheresis treatments. Using computerized molecular modeling, we developed multimeric VEGF molecules comprised of single-chain VEGF 165 dimers (scVEGF 165 ). A short peptide linker hampers intrachain dimerization to induce assembly preferably as tetrameric molecules as visualized in negative staining electron microscopy. scVEGF 165 multimers possess 1.2-fold higher affinity for sFlt-1 as compared to the available antibodies or monomeric VEGF. Consequently, scVEGF multimers have the ability to competitively release sFlt-1 bound PlGF and, in particular, VEGF. In ex vivo adsorption experiments using serum samples from patients with preeclampsia, scVEGF multimers reduce sFlt-1 levels by 85% and increase PlGF and VEGF levels by 20- and 9-fold, respectively. Finally, performance and stability of sFlt-1 capturing scVEGF 165 multimers were scrutinized on different matrices of which biocompatible agarose matrix yielded optimal results. We introduce the first VEGF-based highly efficient sFlt-1 apheresis system that is directly applicable in vivo due to utilization of inert agarose matrix, using a homomultimeric form of VEGF 165 to restore the angiogenic balance in preeclampsia.

scholarly journals Expression of Vascular Endothelial Growth Factor Protein in Both Serum Samples and Excised Tumor Tissues of Breast Carcinoma Patients

2016 ◽  
Vol 12 (3-4) ◽  
pp. 152-161
Author(s):  
Halla Mohamed Ragab ◽  
HebatAllah Mohamed Shaaban ◽  
Nabila Abd El Maksoud ◽  
Samah Mohamed Radwan ◽  
Wafaa Abd Elaziz ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Breast Carcinoma ◽  
Vascular Endothelial ◽  
Serum Samples ◽  
Tumor Tissues ◽  
Endothelial Growth Factor

scholarly journals Determination of vascular endothelial growth factor concentration in serum of patients with varicose veins after conventional phlebectomy and hybrid treatment

2019 ◽  
Vol 85 (2) ◽  
pp. 33-37 ◽  
Author(s):  
F. Adylkhanov ◽  
A. Fursov ◽  
Y. Noso
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Varicose Veins ◽  
Standard Technique ◽  
Control Group ◽  
Vascular Endothelial ◽  
Serum Samples ◽  
Hybrid Treatment ◽  
Endothelial Growth Factor ◽  
Vegf Level

Objective. To study the change of the vascular endothelial growth factor (VEGF) level and the incidence of recurrence of varicose veins after conventional phlebectomy and hybrid treatment. Materials and methods. Conventional phlebectomy was performed according to standard technique. Hybrid treatment consisted of combination of methods, including laser ablation, ultrasound guided foam form sclerotherapy (aethoxysklerol 1-3%), high degree of ligation (HL), total or partial stripping of saphenous vein. The treatment was personalized to every patient. This study included 134 patients, that were divided into two groups, depending on the method of treatment. Serum samples were collected from patients before operation and in 3-12 months after operation. Control group included 20 healthy persons. We analyzed mean concentration and change of the VEGF levels in patients’ serum before and after treatment. Results. Mean levels of VEGF decreased in 3.95 – 5.38 times after the treatment. Also, recurrent cases were estimated. In the case of the recurrence, VEGF levels were higher than in non-recurrent cases. Conclusions. Therefore, results of the study suggest an association between the recurrence of varicose veins and the change of VEGF level.

scholarly journals Serum Level of Vascular Endothelial Growth Factor (VEGF) can be used to Assess Response of Radiation Therapy in Cervical Cancer

2014 ◽  
pp. 40-45
Author(s):  
Ferry Armanza ◽  
Andrijono Andrijono ◽  
Bambang Sutrisna
Keyword(s):  
Cervical Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Radiation Therapy ◽  
Growth Factor ◽  
Roc Curves ◽  
Vascular Endothelial ◽  
Serum Samples ◽  
Before And After ◽  
Post Radiation ◽  
Endothelial Growth Factor

Objective: To compare the sensitivity and specificity of Squamous Cell Carcinoma (SCC) and Vascular Endothelial Growth Factor (VEGF) levels to assess the response of radiation therapy. Method: The study was conducted by the method of analytic observational cohort study in 24 patients with cervical cancer stage II-B and III-B in RSCM that met inclusion criteria. Examination of VEGF and SCC in serum samples was performed in the Prodia Laboratory Jakarta. The examination was conducted twice before and after radiation therapy. The subjects were treated by radiation therapy/chemoradiation according to standard procedures. After the completion of radiation was declared, the response of radiation therapy was conducted by clinical assessment. Result: Of the 24 subjects, we obtained a mean level of SCC pre-radiation was 23.43 ± 5.84 ng/ml and post-radiation was 2.19 ± 0.68 ng/ml. The mean VEGF pre-radiation was 790.41 ± 111.06 pg/ml and post-radiation was 497.47 ± 79.26 pg/ml. ROC curves of each tumor marker obtained SCC pre-radiation AUC 40%, p 0.53 (CI 0.18-0.68) and SCC post-radiation AUC 48.1%, p 0.91 (CI 0.21-0,75) can not be used as a diagnostic and prognostic factors of response to radiation therapy. VEGF pre-radiation produced an AUC of 17.5%, p 0.04 (CI 0.00-0.36), thus cannot be used as a prognostic factor for response to radiation therapy. VEGF after radiation produced an AUC of 92.5%, p 0.01 (CI 0.81-1.00), thus can be a diagnostic factor for response to radiation therapy. VEGF post-radiation with cut-off point 614.75 pg/ml had a sensitivity 80%, specificity 75%, NDP 94.12%, NDN 42.86%; RKP 3.2; RKN 0.26 and accuracy 79.16%. There is a significant correlation between the decrease of serum VEGF level post-radiation and a positive response of radiation therapy (p 0.01, CI 1.00-3.23). Conclusion: Examination of VEGF levels can be used to assess the response of radiation therapy with a sensitivity of 80% and specificity of 75%.  Keywords: cervical cancer, SCC, therapeutic response, VEGF

Sign in / Sign up

Export Citation Format

Share Document